Steglatro (ertugliflozin) is a type 2 diabetes oral medication in the SGLT-2 inhibitor class of drugs. It blocks glucose from being reabsorbed by the kidneys. Excess glucose is released in the urine. Medications in the SGLT-2 inhibitor class may offer heart and kidney benefits for people with cardiovascular disease. Because type 2 diabetes medications act in different ways to lower blood glucose levels, providers will often prescribe multiple drugs to a patient. Several of the more popular combinations of oral drugs can be prescribed together in a single pill. Each medication has its own side effects. Read labels carefully to be sure you know what they are.